A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels

Blood

Volumn 109, Issue 9, 2007, Pages 3713-3724

  Viel, Kevin R ^a,b   Machiah, Deepa K ^a   Warren, Diane M ^c   Khachidze, Manana ^a   Buil, Alfonso ^d   Fernstrom, Karl ^a   Souto, Juan C ^d   Peralta, Juan M ^c,e   Smith, Todd ^f   Blangero, John ^c   Porter, Sandra ^f   Warren, Stephen T ^a   Fontcuberta, Jordi ^d   Soria, Jose M ^d   Flanders, W Dana ^b   Almasy, Laura ^c   Howard, Tom E ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^f Geospiza Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ARTICLE; BLOOD GROUP ABO SYSTEM; CONTROLLED STUDY; DNA POLYMORPHISM; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOPHILIA;

EID: 34247330151     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-06-026104     Document Type: Article

References (85)

1. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152-155.
2. Bank I, Libourel EJ, Middeldorp S, et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost. 2005;3:79-84.
3. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343:457-462.
4. Cortellaro M, Boschetti C, Cofrancesco E, et al. The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group. Arterioscler Thromb. 1992;12:1063-1070.
5. Wells PS, Langlois NJ, Webster MA, Jaffey J, Anderson JA. Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada: is it necessary to define a new upper reference range for factor VIII? Thromb Haemost. 2005;93:842-846.
6. Thompson AR. Structure and function of the factor VIII gene and protein. Semin Thromb Hemost. 2003;29:11-22.
7. Conlan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost. 1993;70:380-385.
8. Balleisen L, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population, I: baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost. 1985;54:475-479.
9. Tracy RP, Bovill EG, Fried LP, et al. The distribution of coagulation factors VII and VIII and fibrinogen in adults over 65 years: results from the Cardiovascular Health Study. Ann Epidemiol. 1992;2:509-519.
10. Lowe GD, Rumley A, Woodward M, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey, I: illustrative reference ranges by age, sex and hormone use. Br J Haematol. 1997;97:775-784.
11. Lindeberg S, Berntorp E, Nilsson-Ehle P, Terent A, Vessby B. Age relations of cardiovascular risk factors in a traditional Melanesian society: the Kitava Study. Am J Clin Nutr. 1997;66:845-852.
12. Yarnell JW, Sweetnam PM, Rumley A, Lowe GD. Lifestyle factors and coagulation activation markers: the Caerphilly Study. Blood Coagul Fibrinolysis. 2001;12:721-728.
13. Schlit AF, Grandjean P, Donnez J, Lavenne E. Large increase in plasmatic 11-dehydro-TxB2 levels due to oral contraceptives. Contraception. 1995;51:53-58.
14. Chang SJ, Koh SB, Cha BS, Park JK. Job characteristics and blood coagulation factors in Korean male workers. J Occup Environ Med. 2002;44:997-1002.
15. Geffken DF, Cushman M, Burke GL, Polak JF, Sakkinen PA, Tracy RP. Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol. 2001;153:242-250.
16. Cushman M, Yanez D, Psaty BM, et al. Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Cardiovascular Health Study Investigators. Am J Epidemiol. 1996;143:665-676.
17. Green D, Ruth KJ, Folsom AR, Liu K. Hemostatic factors in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler Thromb. 1994;14:686-693.
18. Jeremic M, Weisert O, Gedde-Dahl TW. Factor VIII (AHG) levels in 1016 regular blood donors: the effects of age, sex, and ABO blood groups. Scand J Clin Lab Invest. 1976;36:461-466.
19. McCallum CJ, Peake IR, Newcombe RG, Bloom AL. Factor VIII levels and blood group antigens. Thromb Haemost. 1983;50:757.
20. Mohanty D, Ghosh K, Marwaha N, Kaur S, Chauhan AP, Das KC. Major blood group antigens: a determinant of factor VIII levels in blood? Thromb Haemost. 1984;51:414.
21. Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII and factor IX in a twin population: evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet. 1985;37:89-101.
22. Souto JC, Almasy L, Muniz-Diaz E, et al. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol. 2000;20:2024-2028.
23. Balleisen L, Assmann G, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population, II: baseline data on the relation to blood pressure, blood glucose, uric acid, and lipid fractions. Thromb Haemost. 1985;54:721-723.
24. Cadroy Y, Daviaud P, Saivin S, Sie P, Boneu B. Distribution of 16 hemostatic laboratory variables assayed in 100 blood donors. Nouv Rev Fr Hematol. 1990;32:259-264.
25. Morange PE, Tregouet DA, Frere C, et al. Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. Br J Haematol. 2005;128:91-99.
26. Miller CH, Haff E, Platt SJ, et al. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost. 2003;1:2191-2197.
27. Weiss HJ, Hoyer IW. Von Willebrand factor: dissociation from antihemophilic factor procoagulant activity. Science. 1973;182:1149-1151.
28. Weiss HJ, Sussman, II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor: studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest. 1977;60:390-404.
29. Tuddenham EG, Lane RS, Rotblat F, et al. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br J Haematol. 1982;52:259-267.
30. van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood. 2000;95:3678-3682.
31. Souto JC, Almasy L, Borrell M, et al. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation. 2000;101:1546-1551.
32. de Lange M, Snieder H, Ariens RA, Spector TD, Grant PJ. The genetics of haemostasis: a twin study. Lancet. 2001;357:101-105.
33. Kamphuisen PW, Houwing-Duistermaat JJ, van Houwelingen HC, Eikenboom JC, Bertina RM, Rosendaal FR. Familial clustering of factor VIII and von Willebrand factor levels. Thromb Haemost. 1998;79:323-327.
34. Vossen CY, Hasstedt SJ, Rosendaal FR, et al. Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family. J Thromb Haemost. 2004;2:242-247.
35. Souto JC, Almasy L, Borrell M, et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. Am J Hum Genet. 2000;67:1452-1459.
36. Soria JM, Almasy L, Souto JC, et al. A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility. Blood. 2003;101:163-167.
37. Berger M, Mattheisen M, Kulle B, et al. High factor VIII levels in venous thromboembolism show linkage to imprinted loci on chromosomes 5 and 11. Blood. 2005;105:638-644.
38. Kemball-Cook G, Tuddenham EG, Wacey AI. The factor VIII structure and mutation resource site: HAMSTeRS version 4. Nucleic Acids Res. 1998;26:216-219.
39. Machiah DK, Viel K, Almasy L, et al. A common SNP in the factor VIII (f-VIII) gene encodes a conservative aspartate to glutamate substitution (Asp1241Glu) in the B-domain that influences f-VIII activity levels [abstract]. Blood. 2003;102:55a. Abstract 181.
40. Scanavini D, Legnani C, Lunghi B, Mingozzi F, Palareti G, Bernardi F. The factor VIII D1241E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levels. Thromb Haemost. 2005;93:453-456.
41. Mansvelt EP, Laffan M, McVey JH, Tuddenham EG. Analysis of the F8 gene in individuals with high plasma factor VIII:C levels and associated venous thrombosis. Thromb Haemost. 1998;80:561-565.
42. Brummer J, Groth J, Flayeh R, Wagener C, Jung R. Absence of mutations at the APC interacting sites of factor VIII in Caucasians. Thromb Haemost. 2002;87:170.
43. Hooper WC, Dilley A, Austin H, et al. Absence of mutations at APC cleavage sites Arg306 in factor V and Arg336, Arg562 in factor VIII in African-Americans. Thromb Haemost. 1998;79:236.
44. Kamphuisen PW, Eikenboom JC, Rosendaal FR, et al. High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br J Haematol. 2001;115:156-158.
45. Roelse JC, Koopman MM, Buller HR, et al. Absence of mutations at the activated protein C cleavage sites of factor VIII in 125 patients with venous thrombosis. Br J Haematol. 1996;92:740-743.
46. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature. 1984;312:326-330.
47. Figueiredo MS, Brownlee GG. cis-acting elements and transcription factors involved in the promoter activity of the human factor VIII gene. J Biol Chem. 1995;270:11828-11838.
48. McGlynn LK, Mueller CR, Begbie M, Notley CR, Lillicrap D. Role of the liver-enriched transcription factor hepatocyte nuclear factor 1 in transcriptional regulation of the factor V111 gene. Mol Cell Biol. 1996;16:1936-1945.
49. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
50. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306-Thr) associated with resistance to activated protein C. Blood. 1998;91:1140-1144.
51. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
52. Howard TE, Marusa M, Channell C, Duncan A. A patient homozygous for a mutation in the prothrombin gene 3′-untranslated region associated with massive thrombosis. Blood Coagul Fibrinolysis. 1997;8:316-319.
53. National Heart, Lung, and Blood Institute Program for Genomic Applications. SeattleSNPs. http://pga.gs.washington.edu. Accessed November 2004.
54. Ewing B, Hillier L, Wendl MC, Green P. Base-calling of automated sequencer traces using phred, I: accuracy assessment. Genome Res. 1998;8:175-185.
55. Ewing B, Green P. Base-calling of automated sequencer traces using phred, II: error probabilities. Genome Res. 1998;8:186-194.
56. Zerylnick C, Torroni A, Sherman SL, Warren ST. Normal variation at the myotonic dystrophy locus in global human populations. Am J Hum Genet. 1995;56:123-130.
57. Karolchik D, Baertsch R, Diekhans M, et al. The UCSC Genome Browser Database. Nucl Acids Res. 2003;31:51-54.
58. Wacey AI, Kemball-Cook G. The Haemophilia A Mutation, Structure, Test and Resource Site. http://europium.csc.mrc.ac.uk/WebPages/Main/main.htm. Accessed November 2004.
59. National Center for Biotechnology Information, National Library of Medicine. The Single Nucleotide Polymorphism Database (dbSNP) of Nucleotide Sequence Variation. http://www.ncbi.nlm.nih.gov/SNP/. Accessed November 2004.
60. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet. 1998;62:1198-1211.
61. Zhao JH. 2LD, GENECOUNTING and HAP: computer programs for linkage disequilibrium analysis. Bioinformatics. 2004;20:1325-1326.
62. Almasy L, Dyer TD, Blangero J. Bivariate quantitative trait linkage analysis: pleiotropy versus coincident linkages. Genet Epidemiol. 1997;14:953-958.
63. Blangero J, Goring HH, Kent JW Jr, et al. Quantitative trait nucleotide analysis using Bayesian model selection. Hum Biol. 2005;77:541-559.
64. Ruppert D, Wand MP, Carroll RJ. Semiparametric Regression. Cambridge, NY: Cambridge University Press; 2003.
65. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology. 1995;6:356-365.
66. Motulsky HJ, Ransnas LA. Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J. 1987;1:365-374.
67. Folsom AR, Pankow JS, Tracy RP, et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol. 2001;88:112-117.
68. Kreuz W, Stoll M, Junker R, et al. Familial elevated factor VIII in children with symptomatic venous thrombosis and post-thrombotic syndrome: results of a multicenter study. Arterioscler Thromb Vasc Biol. 2006;26:1901-1906.
69. Reitsma PH, Branger J, Van Den Blink B, Weijer S, Van Der Poll T, Meijers JC. Procoagulant protein levels are differentially increased during human endotoxemia. J Thromb Haemost. 2003;1:1019-1023.
70. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1998.
71. De Visser MC, Sandkuijl LA, Lensen RP, Vos HL, Rosendaal FR, Bertina RM. Linkage analysis of factor VIII and von Willebrand factor loci as quantitative trait loci. J Thromb Haemost. 2003;1:1771-1776.
72. Lindeberg S, Berntorp E, Carlsson R, Eliasson M, Marckmann P. Haemostatic variables in Pacific Islanders apparently free from stroke and ischaemic heart disease: the Kitava Study. Thromb Haemost. 1997;77:94-98.
73. Miller CH, Dilley AB, Drews C, Richardson L, Evatt B. Changes in von Willebrand factor and factor VIII levels during the menstrual cycle. Thromb Haemost. 2002;87:1082-1083.
74. Meade TW, Brozovic M, Chakrabarth R, Howarth DJ, North WR, Stirling Y. An epidemiological study of the haemostatic and other effects of oral contraceptives. Br J Haematol. 1976;34:353-364.
75. Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Thromb Haemost. 1999;82:1456-1461.
76. Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature. 1984;312:342-347.
77. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature. 1984;312:337-342.
78. Langner KD, Bird RE, McCandliss R, et al. Synthesis of biologically active deletion mutants of human factor VIII:C. Behring Inst Mitt. 1988:16-25.
79. Eaton DL, Wood WI, Eaton D, et al. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry. 1986;25:8343-8347.
80. Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci U S A. 1986;83:5939-5942.
81. Burke RL, Pachl C, Quiroga M, et al. The functional domains of coagulation factor VIII:C. J Biol Chem. 1986;261:12574-12578.
82. Pittman DD, Tomkinson KN, Kaufman RJ. Post-translational requirements for functional factor V and factor VIII secretion in mammalian cells. J Biol Chem. 1994;269:17329-17337.
83. Zhang B, Kaufman RJ, Ginsburg D. LMAN1 and MCFD2 form a cargo receptor complex and interact with coagulation factor VIII in the early secretory pathway. J Biol Chem. 2005;280:25881-25886.
84. Soria JM, Almasy L, Souto JC, et al. Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood. 2000;95:2780-2785.
85. Soria JM, Almasy L, Souto JC, Sabater-Lleal M, Fontcuberta J, Blangero J. The F7 gene and clotting factor VII levels: dissection of a human quantitative trait locus. Hum Biol. 2005;77:561-575.